Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 22.1
edited by manuelmenendez
on 2025/01/29 18:44
Change comment: There is no comment for this version
To version 1.1
edited by manuelmenendez
on 2025/01/27 22:53
Change comment: Collab created by manuelmenendez

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for neurodegenerative diseases// =
5 += My Collab's Extended Title =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +My collab's subtitle
9 9  )))
10 10  )))
11 11  
... ... @@ -13,74 +13,18 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -== **Overview** ==
17 +* Notice how the table of contents on the right
18 +* is automatically updated
19 +* to hold this page's headers
19 19  
20 -The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on:
21 += Who has access? =
21 21  
22 -* **Axis 1**: Etiology (genetic or other causes of diseases).
23 -* **Axis 2**: Molecular Markers (biomarkers).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 -
28 -
29 -This methodology enables:
30 -
31 -* Greater precision in diagnosis.
32 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
33 -* Stratification of patients for personalized treatment.
34 -
35 -== **Diagnostic Axes** ==
36 -
37 -* (((
38 -**Axis 1: Etiology**
39 -
40 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
41 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
42 -* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
23 +Describe the audience of this collab.
43 43  )))
44 -* (((
45 -**Axis 2: Molecular Markers**
46 46  
47 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
48 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
49 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
50 -)))
51 -* (((
52 -**Axis 3: Neuroanatomoclinical**
53 53  
54 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
55 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
56 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
57 -)))
58 -
59 -== **Applications** ==
60 -
61 -This system enhances:
62 -
63 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
64 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
65 -
66 -== Who has access? ==
67 -
68 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
69 -
70 -== How to Contribute ==
71 -
72 -* Access the `/docs` folder for guidelines.
73 -* Use `/code` for the latest AI pipelines.
74 -* Share feedback and ideas in the wiki discussion pages.
75 -
76 -== Key Objectives ==
77 -
78 -* Develop interpretable AI models for diagnosis and progression tracking.
79 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
80 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
81 -)))
82 -
83 -
84 84  (% class="col-xs-12 col-sm-4" %)
85 85  (((
86 86  {{box title="**Contents**"}}
... ... @@ -87,14 +87,6 @@
87 87  {{toc/}}
88 88  {{/box}}
89 89  
90 -== Main contents ==
91 -
92 -* `/docs`: Documentation and contribution guidelines.
93 -* `/code`: Machine learning pipelines and scripts.
94 -* `/data`: Sample datasets for testing.
95 -* `/outputs`: Generated models, visualizations, and reports.
96 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
97 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
98 -* [[to-do-list>>to-do-list]]
33 +
99 99  )))
100 100  )))
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[0]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -Collabs.neurodiagnoses._.groups.collab-neurodiagnoses-viewer
Levels
... ... @@ -1,1 +1,0 @@
1 -view,comment
XWiki.XWikiRights[1]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -Collabs.neurodiagnoses._.groups.collab-neurodiagnoses-editor
Levels
... ... @@ -1,1 +1,0 @@
1 -view,comment,edit
XWiki.XWikiRights[2]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -Collabs.neurodiagnoses._.groups.collab-neurodiagnoses-administrator
Levels
... ... @@ -1,1 +1,0 @@
1 -view,comment,edit,delete
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view